SE448275B - Sett att utvinna antihemofilifaktorn viii - Google Patents
Sett att utvinna antihemofilifaktorn viiiInfo
- Publication number
- SE448275B SE448275B SE7812967A SE7812967A SE448275B SE 448275 B SE448275 B SE 448275B SE 7812967 A SE7812967 A SE 7812967A SE 7812967 A SE7812967 A SE 7812967A SE 448275 B SE448275 B SE 448275B
- Authority
- SE
- Sweden
- Prior art keywords
- plasma
- factor viii
- glycine
- blood
- heparin
- Prior art date
Links
- 229960000301 factor viii Drugs 0.000 title claims description 25
- 210000002381 plasma Anatomy 0.000 claims description 35
- 238000000034 method Methods 0.000 claims description 30
- 210000004369 blood Anatomy 0.000 claims description 26
- 239000008280 blood Substances 0.000 claims description 26
- 229920000669 heparin Polymers 0.000 claims description 23
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 22
- 108010054218 Factor VIII Proteins 0.000 claims description 22
- 102000001690 Factor VIII Human genes 0.000 claims description 22
- 239000002202 Polyethylene glycol Substances 0.000 claims description 22
- 239000011575 calcium Substances 0.000 claims description 22
- 229910052791 calcium Inorganic materials 0.000 claims description 22
- 229920001223 polyethylene glycol Polymers 0.000 claims description 22
- 102100026735 Coagulation factor VIII Human genes 0.000 claims description 21
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims description 21
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 20
- 229960002897 heparin Drugs 0.000 claims description 20
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 19
- 239000003146 anticoagulant agent Substances 0.000 claims description 17
- 229940127219 anticoagulant drug Drugs 0.000 claims description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 15
- 239000002244 precipitate Substances 0.000 claims description 11
- 239000004471 Glycine Substances 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 238000011084 recovery Methods 0.000 claims description 4
- MWLUPTBKTSQFNA-UHFFFAOYSA-N 2-aminoacetic acid;ethanol Chemical compound CCO.NCC(O)=O MWLUPTBKTSQFNA-UHFFFAOYSA-N 0.000 claims description 3
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 claims description 3
- 230000001376 precipitating effect Effects 0.000 claims description 3
- -1 glycine-polyethylene Chemical group 0.000 claims description 2
- 229940127090 anticoagulant agent Drugs 0.000 claims 1
- 238000007796 conventional method Methods 0.000 claims 1
- 238000000926 separation method Methods 0.000 claims 1
- 238000001556 precipitation Methods 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 150000002500 ions Chemical class 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- 238000005194 fractionation Methods 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 5
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- YBHYYFYQHRADCQ-UHFFFAOYSA-N 2-aminoacetic acid;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical class NCC(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O YBHYYFYQHRADCQ-UHFFFAOYSA-N 0.000 description 1
- GHCZTIFQWKKGSB-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;phosphoric acid Chemical compound OP(O)(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O GHCZTIFQWKKGSB-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 101100137177 Drosophila melanogaster polyph gene Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 101100221809 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cpd-7 gene Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 230000001112 coagulating effect Effects 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 229920006158 high molecular weight polymer Polymers 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 125000006353 oxyethylene group Chemical group 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- FYKDNWHPKQOZOT-UHFFFAOYSA-M sodium;dihydrogen phosphate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].OP(O)([O-])=O.OC(=O)CC(O)(C(O)=O)CC(O)=O FYKDNWHPKQOZOT-UHFFFAOYSA-M 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/829—Blood
- Y10S530/83—Plasma; serum
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA293,393A CA1074698A (en) | 1977-12-19 | 1977-12-19 | Method of collecting anti-hemophilic factor viii from blood and blood plasma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SE7812967L SE7812967L (sv) | 1979-06-20 |
| SE448275B true SE448275B (sv) | 1987-02-09 |
Family
ID=4110324
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE7812967A SE448275B (sv) | 1977-12-19 | 1978-12-18 | Sett att utvinna antihemofilifaktorn viii |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US4203891A (ja) |
| JP (1) | JPS596288B2 (ja) |
| AT (1) | AT365453B (ja) |
| CA (1) | CA1074698A (ja) |
| DE (1) | DE2854381A1 (ja) |
| FR (1) | FR2411608A1 (ja) |
| GB (1) | GB1577504A (ja) |
| SE (1) | SE448275B (ja) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT359646B (de) * | 1979-04-19 | 1980-11-25 | Immuno Ag | Verfahren zur herstellung von nebenwirkungs- freien plasmafraktionen |
| US4278594A (en) * | 1979-06-19 | 1981-07-14 | David Amrani | Process for separation and isolation of AHF, von Willebrand's ristocetin cofactor (VWF:RCF) and fibronectin from blood plasma |
| SE448945B (sv) * | 1979-12-20 | 1987-03-30 | Blombaeck E G B | Forfarande for rening och /eller koncentrering av faktor viii-komplexet |
| US4289691A (en) * | 1980-01-18 | 1981-09-15 | The Canadian Red Cross Society | Method of obtaining intermediate purity factor VIII |
| DE3163003D1 (en) * | 1980-01-18 | 1984-05-17 | Canadian Red Cross | Method of obtaining factor viii |
| US4405612A (en) * | 1980-05-23 | 1983-09-20 | Riker Laboratories, Inc. | Heparin web compositions |
| WO1981003277A1 (en) * | 1980-05-23 | 1981-11-26 | Riker Laboratories Inc | Heparin web and process |
| US4305871A (en) * | 1980-09-02 | 1981-12-15 | Edward Shanbrom | Method of selectively increasing yield and purity of certain cryoprecipitate proteins by heating |
| US4359463A (en) * | 1980-11-26 | 1982-11-16 | Rock Gail A | Stabilization of Factor VIII activity in whole blood or blood plasma |
| EP0062456B1 (en) * | 1981-04-08 | 1988-12-21 | United Kingdom Atomic Energy Authority | Blood fractionation improvement |
| US4479799A (en) * | 1981-05-21 | 1984-10-30 | Riker Laboratories, Inc. | Hypodermic syringe containing microfibers of an amorphous heparin salt |
| EP0081482A1 (en) * | 1981-06-18 | 1983-06-22 | E. G. Birger Blombäck | A process in purification and concentration of the factor viii complex |
| CA1178887A (en) * | 1981-10-01 | 1984-12-04 | Gail A. Rock | Factor viii concentrates prepared from heparinized plasma by the application of a cold precipitation technique |
| US4361509A (en) * | 1981-12-14 | 1982-11-30 | Scripps Clinic And Research Foundation | Ultrapurification of factor VIII using monoclonal antibodies |
| USRE32011E (en) * | 1981-12-14 | 1985-10-22 | Scripps Clinic And Research Foundation | Ultrapurification of factor VIII using monoclonal antibodies |
| US4397841A (en) * | 1982-06-28 | 1983-08-09 | Monsanto Company | Production of blood coagulation factor VIII:C |
| DE3247563A1 (de) * | 1982-12-22 | 1984-06-28 | Rovema Verpackungsmaschinen GmbH, 6301 Fernwald | Vorrichtung zur zufuehrung von faltschachtelzuschnitten zu einer kartoniermaschine |
| AT379510B (de) * | 1983-05-20 | 1986-01-27 | Immuno Ag | Verfahren zur herstellung einer faktor viii (ahf) -haeltigen praeparation |
| HUT40311A (en) * | 1983-06-03 | 1986-12-28 | Kiskunhalasi Aag | Process for producing protein concentrates, blood-curd and nutriments from blood and its elements |
| US5149787A (en) * | 1984-05-22 | 1992-09-22 | The Blood Center Research Foundation | Method for maintaining intact, non-degraded factor VIII/von-Willebrand factor during blood processing |
| US4710381A (en) * | 1984-05-22 | 1987-12-01 | The Blood Center Of Southeastern Wisconsin | Method for maintaining intact, non-degraded factor VIII/von-Willebrand factor during blood processing |
| JPS6154597A (ja) * | 1984-08-25 | 1986-03-18 | 松下電工株式会社 | 半導体式熱感知器 |
| US4928603A (en) * | 1984-09-07 | 1990-05-29 | The Trustees Of Columbia University In The City Of New York | Method of preparing a cryoprecipitated suspension and use thereof |
| US4543210A (en) * | 1984-10-04 | 1985-09-24 | Miles Laboratories, Inc. | Process for producing a high purity antihemophilic factor concentrate |
| GB8505882D0 (en) * | 1985-03-07 | 1985-04-11 | Central Blood Lab Authority | Purification of blood coagulation factor viii |
| DE3684459D1 (de) * | 1986-03-27 | 1992-04-23 | Octapharma Ag | Verfahren zur herstellung eines hochgereinigten antihaemophilie-faktors. |
| USH1509H (en) * | 1989-06-09 | 1995-12-05 | Eran; Harutyun | Heparin enhanced process for separating antihemophilic factor (Factor VIII) and fibronectin from cryoprecipitate |
| DE4230513C1 (de) * | 1992-09-11 | 1994-03-31 | Fresenius Ag | Vorrichtung zur Entfernung von Aluminiumionen aus Blut und Lösung zur Verwendung in der Vorrichtung |
| DE19634313A1 (de) * | 1996-08-24 | 1998-02-26 | Behringwerke Ag | Methode zur Stabilisierung von Plättchen |
| US20020077276A1 (en) * | 1999-04-27 | 2002-06-20 | Fredeking Terry M. | Compositions and methods for treating hemorrhagic virus infections and other disorders |
| SE1050124A1 (sv) * | 2010-02-08 | 2011-08-09 | Linkoping Biocontrols Ab | Stabil lösning |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2847348A (en) * | 1954-05-27 | 1958-08-12 | Ortho Pharma Corp | Plasma fractionation and product therefrom |
| US2867567A (en) * | 1955-01-21 | 1959-01-06 | Nat Res Dev | Process of preparing anti-haemophilic globulin |
| US3548052A (en) * | 1964-10-27 | 1970-12-15 | Canada Packers Ltd | Heparin compositions and methods of using same |
| US3453194A (en) * | 1966-08-03 | 1969-07-01 | Dow Corning | Anticoagulant surfaces produced by radiation grafting heparin to a silicone substrate |
| US3652530A (en) * | 1967-08-28 | 1972-03-28 | American Nat Red Cross | Antihemophilic factor prepared from blood plasma using polyethylene glycol |
| US3631018A (en) * | 1970-05-01 | 1971-12-28 | Baxter Laboratories Inc | Production of stable high-potency human ahf using polyethylene glycol and glycine to fractionate a cryoprecipitate of ahf concentrate |
| US3682881A (en) * | 1970-10-02 | 1972-08-08 | Baxter Laboratories Inc | Fractionation of plasma using glycine and polyethylene glycol |
| GB1399824A (en) * | 1971-08-16 | 1975-07-02 | Mar Pha Etu Expl Marques | Heparin esters |
| US3803115A (en) * | 1972-05-17 | 1974-04-09 | Baxter Laboratories Inc | Stabilization of ahf using heparin |
| US4069216A (en) * | 1975-06-16 | 1978-01-17 | Edward Shanbrom, Inc. | Simplified methods for preparation of very high purity Factor VIII concentrate |
| US4137223A (en) * | 1977-05-16 | 1979-01-30 | Edward Shanbrom, Inc. | Method of preserving blood plasma II |
-
1977
- 1977-12-19 CA CA293,393A patent/CA1074698A/en not_active Expired
- 1977-12-29 US US05/865,656 patent/US4203891A/en not_active Expired - Lifetime
-
1978
- 1978-01-12 GB GB1199/78A patent/GB1577504A/en not_active Expired
- 1978-12-16 DE DE19782854381 patent/DE2854381A1/de not_active Withdrawn
- 1978-12-18 FR FR7835543A patent/FR2411608A1/fr active Granted
- 1978-12-18 AT AT0902478A patent/AT365453B/de not_active IP Right Cessation
- 1978-12-18 SE SE7812967A patent/SE448275B/sv not_active IP Right Cessation
- 1978-12-19 JP JP53158090A patent/JPS596288B2/ja not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| CA1074698A (en) | 1980-04-01 |
| FR2411608A1 (fr) | 1979-07-13 |
| SE7812967L (sv) | 1979-06-20 |
| DE2854381A1 (de) | 1979-06-21 |
| ATA902478A (de) | 1981-06-15 |
| US4203891A (en) | 1980-05-20 |
| AT365453B (de) | 1982-01-25 |
| JPS5498308A (en) | 1979-08-03 |
| JPS596288B2 (ja) | 1984-02-10 |
| FR2411608B1 (ja) | 1983-05-20 |
| GB1577504A (en) | 1980-10-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SE448275B (sv) | Sett att utvinna antihemofilifaktorn viii | |
| JP3094167B2 (ja) | 免疫血清グロブリンの精製方法 | |
| DE69227055T2 (de) | Verfahren zur Herstellung in industriellem Massstab eines Konzentrates von hochgereinigtem, standardisiertem humanen von Willebrand Faktor, das für therapeutische Anwendung geeignet ist | |
| US4322275A (en) | Fractionation of protein mixtures | |
| US4188318A (en) | Simplified method for preparation of high yield, high purity Factor VIII concentrate | |
| EP0383234B1 (de) | Pasteurisiertes, gereinigtes von Willebrand-Faktor-Konzentrat und Verfahren zu seiner Herstellung | |
| EP0176926B1 (en) | Process for producing a high purity antihemophilic factor concentrate | |
| SE447204B (sv) | Forfarande for att framstella ett intravenost applicerbart serumeggvite-preparat | |
| US4670544A (en) | Process for the manufacture of the cold insoluble globulin and pharmaceutical preparation containing it | |
| US4087415A (en) | Antithrombin III | |
| EP0173242B1 (de) | Verfahren zur Herstellung einer pasteurisierten, isoagglutininfreien Faktor VIII Präparation aus einem Kryopräzipitat | |
| US4164495A (en) | Method of recovering immunoglobulin using a polyol and an alkanoic acid | |
| JPS5867629A (ja) | 抗血友性第８因子の回収方法 | |
| CA1054052A (en) | Simplified method for preparation of high yield, high purity factor viii concentrate | |
| EP0457371A1 (de) | Verfahren zur Gewinnung des Gewebeproteins PP4 | |
| SE459639B (sv) | Foerfarande foer framstaellning av ett faktor viii (amf)-hoegkoncentrat | |
| McMeekin | Preparation and properties of serum and plasma proteins. II. Crystallization of a carbohydrate-containing albumin from horse serum | |
| SE448945B (sv) | Forfarande for rening och /eller koncentrering av faktor viii-komplexet | |
| Surgenor et al. | A system for the separation of the protein components of human plasma. II. The components of the clotting process. | |
| US4075197A (en) | Serum albumin production | |
| US2793203A (en) | Process of preparing stable, highly purified gamma globulin preparations | |
| USRE31268E (en) | Method of recovering immunoglobulin using a polyol and an alkanoic acid | |
| US4057628A (en) | Removal of hepatitis associated antigen from plasma | |
| US4302445A (en) | Method for concentrating and purifying antihemophilic factor or factor VIII | |
| EP0052874A1 (en) | Method for synthesizing procoagulant factor VIII activity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NUG | Patent has lapsed |
Ref document number: 7812967-3 Effective date: 19901106 Format of ref document f/p: F |